Effect Of Atorvastatin On The Expression Of Serum TGF-β₁ In Patients With Diabetic Nephropathy

Objective To investigate the effect of atorvastatin on the expression of serum transforming growth factorβ₁(TGF-β₁) in patients with diabetic nephropathy(DN).Methods 60 case of patients with DN(CKD 2 and 3 period) were randomly divided into 3 groups.Group 1 was control group, did not use atorvastatin.Groups 2 and 3 were treated with atorvastatin 20mg/d and 40mg/d properly.Groups 2 and 3 were treated for 16weeks. The serum levels of TGF-β₁,β₂-microglobulin(MG),serum creatinin(Scr), serum uric acid(UA),serum cholesterol(TC),serum glycerol(TG) and 24-hour urinary albumin of control group and treatment groups patients were detected before treatment and after treatment for 6,12,16 weeks.Results Serum levels of TGF-β₁,β₂-MG,Scr,UA,TC,TG and 24h urinary albumin had no significant difference between control group and treatment groups before treatment(P>0.05).There was no significant difference between 6 weeks later and before treatment(p>0.05).The levels of TGF-β₁,β₂-MG,Scr,UA,TC,TG and 24h urinary albumin declined after 12weeks and 16weeks(p<0.05).The levels of TGF-β₁,β₂-MG,Scr,UA,and 24h urinary albumin declined after 16 weeks compared with 12weeks(p<0.05). The serum level of TGF-β₁,β₂-MG,Scr,UA,TC,TG and 24h-urinary albumin of group 20mg/d and group 40mg/d had significant statistical significance(p<0.01).Conclusions Atorvastatin may inhibit renal interstitial fibrosis of diabetic nephropathy through suppression of expression of TGF-β₁ which can reduce extracellullar matrix production. Atorvastatin can delay the evolution of renal function of diabetic nephropathy.